Transforming science into medicine
|
|
- Mabel Beasley
- 5 years ago
- Views:
Transcription
1 Transforming science into medicine
2 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and intends, and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
3 We are committed to developing novel compounds in oncology and immunology that will deliver life-changing innovations for patients. Philip Serlin, CEO
4 4 Who are we? NASDAQ: BLRX Oncology and immunology focus Lead assets: BL-8040 AGI-134 Significant pharma collaborations Attractive investment case Strong balance sheet $44 million (end Q1 2018) Significant upcoming milestones: Top line combination results from phase 2 COMBAT study in pancreatic cancer Results from initial lead-in period of phase 3 GENESIS study in SCM Interim analysis from phase 2b BLAST study in consolidation AML
5 5 Management team PHILIP A. SERLIN Chief Executive Officer MALI ZEEVI Chief Financial Officer HILLIT MANNOR SHACHAR Vice President Business Development ABI VAINSTEIN- HARAS, MD Vice President Clinical & Medical Affairs ELLA SORANI, PhD Vice President Research & Development
6 6 Main pipeline assets PROJECT INDICATION PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY APPROVAL CANCER BL-8040 Stem-cell mobilization Consolidation AML Maintenance AML Gastric cancer Non-small cell lung cancer Pancreatic cancer Pancreatic cancer AGI-134 Solid tumors IMMUNOLOGY BL-1230 Dry eye syndrome OTHER BL-5010 Skin lesions
7 BL-8040 Best-In-Class CXCR4 Antagonist for Multiple Oncology and Hematology Indications For treatment of solid tumors, AML and indications requiring hematopoietic stem cell transplantation
8 8 BL-8040 a best-in-class CXCR4 antagonist targeted at multiple indications BL-8040 is a 14-amino acid synthetic cyclic peptide, high-affinity CXCR4 antagonist with long receptor occupancy (>48 hours) and extended CXCR4 inhibition
9 9 Stem-cell mobilization for patients with hematological malignancies undergoing bone-marrow transplantation Patients with hematological malignancies often require HSC transplant after treatment to restore immune system Significant unmet medical need in SCM Multiple apheresis sessions required 50-70% of patients are poor mobilizers For poor mobilizers, 1-4 daily injections of Mozobil on top of G-CSF are required BL-8040 potentially offers a more effective and convenient mobilization option for patients
10 10 Role of BL-8040 in stem-cell mobilization
11 11 BKTS001 Phase 1/2a study: Stem-cell mobilization in multiple myeloma patients NCT (N=16) Multiple myeloma patients were treated with increasing doses of BL-8040 on top of standard-of-care to assess mobilization of HSCs BL-8040 increases HSC mobilization in a dose-dependent manner Conclusion: BL-8040 increased mobilization of HSCs when added to standard-of-care, enabling collection of sufficient HSCs in single apheresis session
12 12 GENESIS Phase 3 study: Mobilization of HSCs for autologous transplant in multiple myeloma patients Initiated Q Phase 3 randomized, placebo-controlled, safety and efficacy study (n=177): NCT Study design Part 1: Lead-in period - dose confirmation in up to 30 multiple myeloma patients Part 2: Randomized placebo-controlled study in combination with G-CSF in 177 multiple myeloma patients Primary endpoint Proportion of subjects mobilizing 6.0 x 10 6 CD34 + cells/kg with up to 2 apheresis sessions in preparation for auto-hct after a single administration of BL-8040 or placebo + G-CSF BL-8040 potentially offers patients: Robust HSC mobilization Single administration on top of SOC No more than two apheresis sessions
13 13 BL-8040 s potential role in AML treatment pathway increasing leukemic cell exposure to anti-cancer therapies Malignant cells are harbored within protected niche of bone marrow (minimal residual disease), which impacts remission and survival rates BL-8040 mobilizes AML cells to the peripheral blood where they are exposed to anti-cancer therapies, including checkpoint inhibitors
14 14 Role of BL-8040 in AML 1. Bensinger W et al. Bone Marrow Transplant 2009;43:
15 15 BL Phase 1/2a study: Encouraging results in patients with relapsed/refractory AML Phase 1/2a dose escalation/expansion study (n=42): NCT Study design Dose escalation (0.5 to 2.0 mg/kg) with expansion cohort at 1.5mg/kg Safety MTD was not reached, mild/moderate (grade 2/3) transient AEs Efficacy 1. Composite CR for dose selected for expansion (1.5 mg/kg) = 39% 2. Median OS for dose selected for expansion (1.5 mg/kg) of 9.2 months, as compared to historical data of 6.1 months for patients treated only with high-dose Ara-C Comparison of the composite response rate (CR + CRi) of BL high-dose Ara-C, versus high-dose Ara-C alone BL CR, complete response; CRi, complete response with incomplete hematological recovery
16 16 BLAST Phase 2b study: Consolidation therapy for AML patients in first remission Phase 2b double-blind, multi-center placebo controlled study (n=194): NCT Treatment: Two or three cycles (age-based) of high-dose Ara-C in combination with either BL-8040 or placebo Endpoints Relapse free survival (RFS) Toxicity, safety and tolerability of BL-8040 in combination with high-dose Ara-C Minimal residual disease (MRD) Overall survival (OS) BL-8040 potentially offers AML patients prolonged remission and increased overall survival
17 17 BATTLE Phase 1b/2 study: Combination of BL-8040 and atezolizumab in AML patients with high risk of relapse Phase 1b/2 single arm, multi-center open-label study (n=60): NCT To evaluate the safety and efficacy of BL-8040 in combination with atezolizumab for maintenance treatment in AML patients 60 years or older Endpoints Relapse free survival (RFS) Toxicity, safety and tolerability of BL-8040 in combination with atezolizumab Minimal residual disease (MRD) Overall survival (OS) BL atezolizumab potentially offers prolonged remission and better overall survival for elderly AML patients not eligible for transplant
18 18 BL-8040 addressing unmet needs in cancer immunotherapy Despite significant advances in cancer immunotherapy, material needs remain: Improving efficacy of immunotherapy in cold tumors, such as pancreatic cancer Increasing rates and durability of response to existing therapies such as anti-pd1 and anti-pdl1 antibodies BL-8040 may address these needs by: Mobilization of immune cells to peripheral blood circulation Increasing immune cell infiltration into tumors Reducing immunosuppression in tumor microenvironment
19 19 Role of BL-8040 in solid tumors
20 20 Data supporting role of BL-8040 in immunotherapy Robust mobilization Healthy volunteers were treated with BL-8040 or placebo Single administration of BL-8040 triggered substantial mobilization Long receptor occupancy results in prolonged effect ( 24 hours) Tumor infiltration 1 Pre-treatment Microenvironment modification CXCR4 antagonism selectively inhibits the migration of immunosuppressive cells Day 5 BL-8040 monotherapy % specific migration of MDSCs p< MDSCs migration is inhibited by CXCR4 blockade 2 1. Hidalgo, Manuel M., et al. "Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist." (2018): Obermajer et al. Cancer Res 2011;71:
21 21 BL-8040 ongoing collaborations with global pharma companies NCT , NCT , NCT , NCT COMBAT Phase 2a study of BL pembrolizumab (Keytruda ) Study in metastatic pancreatic cancer Open-label multi-center single arm study Commenced September 2016 Top-line results expected H Four phase 1/2 studies planned of BL atezolizumab (Tecentriq TM ) 3 studies in solid tumors (pancreatic, gastric, NSCLC) 1 study in AML Open-label multi-center single arm studies Pancreatic and gastric studies commenced H2 2017
22 22 COMBAT Phase 2a study: Advanced pancreatic cancer Phase 2a open-label, multi-center study in combination with pembrolizumab (n=30): NCT To assess the safety and efficacy of BL-8040 in combination with pembrolizumab (Keytruda) in patients with advanced pancreatic cancer Endpoints Objective response rate according to RECIST 1.1 criteria Disease control rate Progression-free and overall survival Safety and tolerability of the combination Multiple pharmacodynamic parameters Intermediate monotherapy results BL-8040 increased absolute number of immune cells in the blood BL-8040 had long CXCR4 receptor occupancy on lymphocytes BL-8040 caused a reduction of Tregs in peripheral blood BL-8040 increased T-cell tumor infiltration in 75% of patients
23 23 MORPHEUS Phase 1b/2 study: Pancreatic, gastric and NSCLC Phase 1b/2 open-label, multi-center, randomized study in combination with atezolizumab : NCT , NCT Umbrella study to evaluate efficacy and safety of multiple immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic pancreatic, gastric and NSCLC cancers Endpoints Objective response rate (ORR) according to RECIST 1.1 criteria Progression-free and overall survival Safety and tolerability of the combination Multiple pharmacodynamics parameters
24 AGI-134 Cancer Immunotherapy Small molecule inducing hyper-acute, multi-arm immune response targeting tumor-specific neoantigens
25 25 AGI-134 harnessing pre-existing immunity to deliver a patient-specific anti-tumor response Tumors vary from patient to patient in their neoantigen load and identity AGI-134 is a universal drug that evokes a vaccine effect via a unique, hyper-acute, multi-arm mechanism that targets patientspecific neoantigens
26 26 alpha-gal and anti-gal The alpha-gal epitope is abundantly synthesized on glycolipids of non-primates Due to constant exposure to this antigen (expressed by gut flora) humans develop and maintain high levels of anti-gal Abs Xenotransplantation experiments in the 1980 s-90 s found that, when introduced to humans, the alpha-gal-positive tissue was bound by pre-existing human anti-gal antibodies, which were the main cause of the rejection of porcine heart valves AGI-134 is a fully synthetic alpha- Gal glycolipid molecule for intratumoral injection into solid tumors, to induce an immune response against a patient s own neoantigens
27 27 AGI-134 MoA
28 28 Compelling pre-clinical data supports Phase 1 study expected to initiate in mid-2018 Intratumoral administration of AGI-134 induced regression of established melanoma primary tumors in GT KO mice Days post inoculation ASCO-SITC 2018 Abstract 68 / poster E4
29 29 AGI-134 exerts a potent durable abscopal effect and demonstrated synergy with anti-pd1 Single dose of AGI-134 into primary tumor protected mice from secondary tumor development for more than 90 days Combination of AGI-134 with immune checkpoint inhibitor (anti-pd-1) resulted in increased efficacy over monotherapy effect of either agent Inoculate melanoma cells into right flank (1 tumor) and left flank (2 tumor) Treat 1 tumor with PBS or AGI-134 Monitor the appearance of 2 tumors * * *** *** PBS (n=7) AGI-134 (n=8) PBS (n=13) AGI-134 (n=16) anti-pd1 (n=11) AGI anti-pd1 (n=16) ASCO-SITC 2018 Abstract 68 / poster E4 AACR 2016 poster 4862 AACR 2017 poster 616 ASCO 2016 poster 3083
30 Looking ahead
31 31 Principal Milestones for 2018 BL-8040 (Auto SCM) Lead-in results BL-8040 (Pancreatic Cancer) Phase 1/2 top-line results (Merck) 2018 BL-8040 (Allo SCM) Phase 2 top-line results BL-8040 (Multiple Solid Tumors) Phase 1/2 partial results (Genentech) BL-8040 (Pancreatic Cancer) Phase 1/2 partial results (Merck) BL-8040 (r/r AML) Overall survival data BL-8040 (AML Consolidation) Phase 2b interim results AGI-134 (Solid tumors) Phase 1/2a initiation
32 32 Takeaways Focus on oncology and immunology (specifically immuno-oncology) 9 clinical studies ongoing or planned for the next 12 months Read-out from 3-4 Phase 2 studies over the next 12 months Phase 3 registrational study ongoing; read-out from lead-in period mid-2018 Significant collaborations with 3 of the leading global pharma companies
BL-8040: A Novel CXCR4 Antagonist
BL-8040: A Novel CXCR4 Antagonist December 2012 Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," plans,
More informationNewLink Genetics Corporation
Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationCompany Presentation. August 2015
Company Presentation August 2015 Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," plans, scheduled,"
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More information[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015
[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationIMMUNOTHERAPY IMMUNOTHERAPY. 37th Annual JPMorgan Healthcare Conference
NEXT-GENERATION NEXT GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY 37th Annual JPMorgan Healthcare Conference 2 Safe harbor Any statements contained herein that are not statements of historical
More informationONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS
ONCOSEC TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS 0 Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationTargeting the Tumor Locally
ARMING THE IMMUNE SYSTEM TO FIGHT CANCER Targeting the Tumor Locally October 2017 NASDAQ:ONCS Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationCorporate Presentation January 2019
Innovations in Immuno-Oncology Corporate Presentation January 2019 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationReimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking
More information8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks
October 19, 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non- Responder
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationFrédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress
More informationCorporate Presentation
Corporate Presentation October 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine s current expectations
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationIdera Pharmaceuticals 36 th Annual J.P. Morgan Healthcare Conference Idera Pharmaceuticals
Idera Pharmaceuticals 36 th Annual J.P. Morgan Healthcare Conference Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning of
More informationSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationVaccine Therapy for Cancer
Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President for Medical Affairs Chief, Division of General Oncology Dana-Farber Cancer Institute Disclosures for Lawrence
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationTargeting the Tumor Locally
Targeting the Tumor Locally Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations are not descriptions of historical facts regarding OncoSec
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationPiper Jaffray 29 th Annual Healthcare Conference
Piper Jaffray 29 th Annual Healthcare Conference Jonathan Zalevsky, Ph.D. Senior Vice President, Research and Chief Scientific Officer November 28, 2017 This presentation includes forward-looking statements
More informationTargeting the Tumor Locally. April 2018 NASDAQ:ONCS
Targeting the Tumor Locally April 2018 NASDAQ:ONCS Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations are not descriptions of historical
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationDaratumumab: Uncovering a novel mechanism of action for an approved antibody therapy
Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Dr. Kate Sasser, PhD Corporate VP, Translational Research December 14 th, 2017 CD38 is ubiquitously expressed in Myeloma
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JULY 2018 1 Forward-looking statements disclosure This presentation contains forward-looking
More information[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015
[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationNASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.
NASDAQ & TSX: IMV BIO Investor Forum October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationCombination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy
Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures
More informationINTERIM RESULTS AS OF MARCH 31, 2018
INTERIM RESULTS AS OF MARCH 31, 2018 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationMay 31, NCCN Guidelines: T-Cell Lymphomas
May 31, 2017 Maria Rivas, MD Senior Vice-President Global Medical Affairs Merck & Co. Kenilworth - Galloping Hill, +1 908 740 6533 K6-1624G maria.rivas1@merck.com NCCN Guidelines: T-Cell Lymphomas On behalf
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationCorporate Presentation. December, 2018
Corporate Presentation December, 2018 Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationJP Morgan Healthcare Conference. Howard Robin President & CEO January 9, 2018
JP Morgan Healthcare Conference Howard Robin President & CEO January 9, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start
More informationA NEW FRONTIER IN IMMUNO-ONCOLOGY
A NEW FRONTIER IN IMMUNO-ONCOLOGY Proactive One2One Forum London, March 8 th 2018 Dr Richard Goodfellow LSE: SCLP.L CLINICAL STAGE IMMUNO-ONCOLOGY COMPANY Scancell is developing innovative immunotherapies
More information37th Annual J.P. Morgan Healthcare Conference. Howard Robin President & CEO January 8, 2019
37th Annual J.P. Morgan Healthcare Conference Howard Robin President & CEO January 8, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing
More informationActinium Pharmaceuticals, Inc.
, Inc. Actimab-A MRD Consolidation Strategy in MRD+ AML July 10, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or other forward-looking statements regarding
More information[ NASDAQ: MEIP ] August 2014
[ NASDAQ: MEIP ] August 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially from those
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationINTERIM RESULTS AS OF JUNE 30, 2017
INTERIM RESULTS AS OF JUNE 30, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationANNUAL REPORT 2017 PRESS & ANALYST CONFERENCE CALL MARTINSRIED, MARCH 22, 2018
ANNUAL REPORT 2017 PRESS & ANALYST CONFERENCE CALL MARTINSRIED, MARCH 22, 2018 Prof. Dolores J. Schendel, CEO/CSO Dr. Thomas Taapken, CFO Dr. Kai Pinkernell, SVP Clinical Affairs/CMO "Safe Harbor" Statement
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More information